1. Worldometer. Worldometer Covid-19 for Malawi [Internet]. Online. 2022 [cited 2022 Mar 31]. Available from: https://www.worldometers.info/coronavirus/country/malawi/
2. Malawi M of H. Covid-19 Malawi Dashboard [Internet]. 2022 [cited 2022 Mar 31]. Available from: https://covid19.health.gov.mw/
3. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. Khudyakov YE, editor. PLoS One [Internet]. 2021 Jun 23 [cited 2022 May 29];16(6):e0252617. Available from: https://dx.plos.org/10.1371/journal.pone.0252617
4. Glezen WP. Herd protection against influenza. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2006 Dec;37(4):237–43.
5. United Nations Educational, Scientific and Cultural Organization (UNESCO). COVID-19 Educational Disruption and Response [Internet]. 2022 [cited 2022 Jul 15]. Available from: https://en.unesco.org/node/320920
6. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 2021;384(6):533–40.
7. Griffin S. Covid-19: Antibodies protect against reinfection for at least six months, study finds. BMJ [Internet]. 2020;371. Available from: https://www.bmj.com/content/371/bmj.m4961
8. Ren X, Zhou J, Guo J, Hao C, Zheng M, Zhang R, et al. Reinfection in patients with COVID-19: a systematic review. Glob Heal Res Policy [Internet]. 2022;7(1). Available from: https://doi.org/10.1186/s41256-022-00245-3
9. Adrielle dos Santos L, Filho PG de G, Silva AMF, Santos JVG, Santos DS, Aquino MM, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect. 2021;82(3):399–406.
10. Finch E, Lowe R, Fischinger S, de St Aubin M, Siddiqui SM, Dayal D, et al. SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. PLOS Biol [Internet]. 2022 Feb 10;20(2):e3001531. Available from: https://doi.org/10.1371/journal.pbio.3001531
11. Chibwana MG, Jere KC, Kamng’ona R, Mandolo J, Katunga-Phiri V, Tembo D, et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. Wellcome Open Res [Internet]. 2020 Dec 18 [cited 2022 May 29];5:199. Available from: https://wellcomeopenresearch.org/articles/5-199/v2
12. Iface. Sample Size Calculation [Internet]. 2022 [cited 2021 Mar 20]. Available from: http://sampsize.sourceforge.net/iface/
13. Abbott. PANBIOTM COVID-19 IgG/IgM RAPID TEST DEVICE [Internet]. 2022. Available from: https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-igg-igm-antibody-test.html
14. Master R. O. Chisale Sheena Ramazanu2 SEM, Kaminga PKMCAC, Nkhata6 O, Mbakaya BNECBC. Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa A systematic review.pdf [Internet]. Reviews in Medical Virology; 2022. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/rmv.2271
15. Meinus C, Singer R, Nandi B, Jagot O, Becker-Ziaja B, Karo B, et al. SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi. Int J Infect Dis [Internet]. 2022;116:157–65. Available from: https://www.sciencedirect.com/science/article/pii/S1201971221012340
16. Mandolo J, Msefula J, Henrion MYR, Brown C, Moyo B, Samon A, et al. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Med [Internet]. 2021;19(1):303. Available from: https://doi.org/10.1186/s12916-021-02187-y
17. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med [Internet]. 2020;26(8):1200–4. Available from: https://doi.org/10.1038/s41591-020-0965-6
18. Okhuese AV. Estimation of the probability of reinfection with COVID-19 by the susceptible-exposed-infectious-removed-undetectable-susceptible model. JMIR Public Heal Surveill. 2020;6(2).
19. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis. 2021;73(10):1882–6.
20. Nachmias V, Fusman R, Mann S, Koren G. The first case of documented Covid-19 reinfection in Israel. IDCases. 2020;22:e00970.
21. Roy S. COVID-19 Reinfection: Myth or Truth? SN Compr Clin Med. 2020;2(6):710–3.
22. Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosia A. The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. J Clin Microbiol. 2021;59(4).
23. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect [Internet]. 2021 Mar 1;27(3):331–40. Available from: https://doi.org/10.1016/j.cmi.2020.10.020
24. Pérez-Tanoira R, García LL, de Suso MTG, Zapata MR, Serrano TA, Pardo CG, et al. High seroprevalence against sars-cov-2 among faculty of medicine and health sciences personnel and students of the university of alcalá, spain: Contributing factors. Int J Gen Med. 2021;14:7017–24.
25. Torres JP, Piñera C, De La Maza V, Lagomarcino AJ, Simian D, Torres B, et al. Severe acute respiratory syndrome Coronavirus 2 antibody prevalence in blood in a large school community subject to a Coronavirus disease 2019 outbreak: A cross-sectional study. Clin Infect Dis. 2021;73(2):E458–65.
26. Mangal T, Whittaker C, Nkhoma D, Ng'ambi W, Watson O, Walker P, et al. Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. BMJ Open [Internet]. 2021 Jul 1;11(7):e045196. Available from: http://bmjopen.bmj.com/content/11/7/e045196.abstract
27. Yu X-Y, Xu C, Wang H-W, Chang R-J, Dong Y-Q, Tsamlag L, et al. Effective mitigation strategy in early stage of COVID-19 pandemic in China. Infect Dis Poverty [Internet]. 2020;9(1):141. Available from: https://doi.org/10.1186/s40249-020-00759-3